The high seasonal morbidity and mortality associated with both pandemic and seasonal influenza, the continued threat of highly pathogenic avian influenza infections, the development and global spread of antiviral resistance, and the [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) is competing a support contract for scientific, professional and technical expertise for NIAID’s research programs. NIAID conducts and supports basic and applied research [Read more]
A clinical trial of an experimental vaccine to prevent infection with chikungunya virus is now enrolling healthy adult volunteers at sites in the United States. The Phase 1/2 trial, which is sponsored [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) is seeking proposals for nonclinical product development support for promising interventional agents for infectious disease threats. [Read more]
In response to the threat presented by increasing numbers of infections caused by antimicrobial–resistant (AR) and multidrug-resistant (MDR) Gram-negative bacterial pathogens, the NIAID Division of Microbiology and Infectious Diseases (DMID) has established [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement (BAA) expected to be formally released on February 21, 2017. The BAA [Read more]
A Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B has been initiated by Emergency BioSolutions, according to an announcement by the company on Feb 1. UV-4B [Read more]
The 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan (SIP), released this week by the U.S. Department of Health and Human Services, describes the priorities that HHS, in collaboration [Read more]
Pluristem Therapeutics on Dec. 6 announced a milestone in its development program for PLX-R18, which is being evaluated as a medical countermeasure in the treatment of the hematologic components of Acute Radiation [Read more]
National Institute of Allergy & Infectious Diseases (NIAID) has awarded new contracts under a Broad Agency Announcement (BAA) for Development of Therapeutic Products for Biodefense & Emerging Infectious Diseases. The BAA focuses [Read more]
© 2018 STEMAR MEDIA